The article you mentioned only refers to stock portfolio and potential conflicts of interest regarding policy decisions on performing antibody tests.
The statement that was quoted in this discussion is about an entirely unrelated subject: the prevalence of long Covid. The initial claim is that the statement is supported by data from the Office for National Statistics.
If you want to question John Bell's claim regarding the prevalence of long Covid, just check if his statement is corroborated by the data. Either it's supported or not.
There is a very good way to verify the claims: check the data.
Dragging in questions regarding antibody test policies, stock portfolios, and potential conflicts of interest just sound like cheap character assassination attempts that have absolutely no relation with the prevalence of long Covid.
Don't accept things blindly because you agree with them (or the converse), "be a good judge of who is a good judge".
If that's what you're going with then you only need to verify the data to either refute or verify his claim.
Everything else is just noise at this point.
You didn't even bothered to look, did you?
https://www.ons.gov.uk/peoplepopulationandcommunity/healthan...
Sounds like the BMJ dont trust this chap and are questioning his financial interests. Therefore I would question his motives with regard to this article, he isnt very forthcoming which is usually indicative of having something to hide.